Genelux (GNLX) Other financing activities (2023 - 2026)
Genelux's (GNLX) quarterly Other financing activities came in at $13000.0 in Q1 2026, down 7.14% year-on-year from $14000.0 in Q1 2025, and down 7.14% quarter-over-quarter from $14000.0 in Q1 2025.
Genelux (GNLX) Other financing activities (2023 - 2026) Analysis & Trends
Genelux's Other financing activities history runs 4 years deep, the most recent figure standing at $13000.0 for Q1 2026.
- On a quarterly basis, Other financing activities fell 7.14% year-over-year to $13000.0 in Q1 2026; TTM through Mar 2026 was $13000.0, a 7.14% decrease from a year earlier, with the FY2025 full-year figure at $14000.0, down 97.97% from the prior year.
- Other financing activities slipped to $13000.0 in Q1 2026 per GNLX's latest filing, from $14000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $14.5 million in Q1 2023 and bottomed at -$1.3 million in Q4 2023.
- The 4-year median for Other financing activities is $13500.0 (2025), against an average of $2.3 million.
- Across the five-year window, Other financing activities plunged 97.97% in 2025 and slipped 7.14% in 2026, its largest moves.
- Year by year, Other financing activities stood at -$1.3 million in 2023, then jumped by 154.3% to $688000.0 in 2024, then plunged by 97.97% to $14000.0 in 2025, then decreased by 7.14% to $13000.0 in 2026.
- Per Business Quant, the three latest GNLX Other financing activities figures stand at $13000.0 (Q1 2026), $14000.0 (Q1 2025), and $688000.0 (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Genelux | 128.48 Mn | 128.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | -1.27 Mn |
| Dec 31, 2023 | -1.27 Mn |
| Sep 30, 2023 | 1,321.00 |
| Sep 30, 2023 | 1,321.00 |
| Mar 31, 2023 | 14.50 Mn |
| Mar 31, 2023 | 14.50 Mn |